Latest Intellectual Property News

NOVONIX has advanced its position in the battery materials sector with a conditional US$754 million loan commitment from the U.S. Department of Energy and binding offtake agreements with automotive giants Stellantis and PowerCo. These milestones underpin its expansion plans for synthetic graphite production in North America.

Wide Open Agriculture reports a 50% reduction in overheads alongside the development of a novel lupin-based tofu product, positioning itself for growth in the global plant protein market.

Papyrus Australia has taken significant strides in Q4 2024, signing a joint venture terms sheet in Vietnam, appointing new board members, and securing R&D tax incentives, positioning itself for expanded commercialization.

BCAL Diagnostics is poised to launch its innovative BREASTEST® breast cancer diagnostic test in early 2025, backed by recent NATA accreditation, patent acceptance, and a $2.6 million R&D tax offset.

Mesoblast Limited is set to launch Ryoncil®, the first FDA-approved MSC therapy for pediatric steroid-refractory acute graft-versus-host disease, backed by a recent $160 million financing that strengthens its commercial and clinical development efforts.

Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.

Codeifai Limited reports a sharp 59% reduction in quarterly cash burn alongside a 48% rise in cash receipts, driven by its new ConnectQR SaaS platform and a strategic review of its Material Science division.

Li-S Energy has set a new benchmark in lithium-sulfur battery technology, achieving a record 456Wh/kg energy density and successfully powering its first UAV test flights, signaling strong momentum in sustainable battery innovation.

BluGlass Limited has secured over A$4 million in new contracts and filed three US patents for high-power tunable GaN lasers, reinforcing its leadership in visible laser technology and expanding its footprint in strategic photonics markets.

Nanollose Limited has secured $2.1 million in strategic funding to accelerate the commercialisation of its sustainable fibres and soilless growth technologies, marking a pivotal shift from R&D to market-ready products.

Race Oncology has advanced its Phase 1 clinical trial for RC220, submitting ethics approvals and bolstering its cash reserves to $18.78 million following a $5.25 million R&D tax incentive.

Jatcorp Limited faces a sharp revenue drop due to a trademark dispute in China but accelerates growth with new Moroka® products and expanded distribution channels.